Visiting from the United States? GLPInfo has a North American edition with US channels and dollar prices: open the US edition. Canada follows in a later release.
Research → decisions → accessEvidence checked 13 Sep 2026
Follow the science. See what comes next.
A clearer view of the milestones shaping peptide and GLP-1 medicines in the UK, US and EU: confirmed decisions, company targets and clearly labelled estimates, each with its source. What we track · How estimates are made.
Dulaglutide
Eli Lilly · GLP-1 receptor agonist · Peptide (Fc fusion)
Confirmed eventCompany targetRegulator targetEditorial estimateTiming unknown or undatedSafety update
Dashed line: today, 13 Sep 2026. Future windows are conditional. Approval, launch and funded access are separate milestones.
Confirmed · 18 Sep 2014United States
FDA approves Trulicity (dulaglutide) for type 2 diabetes
Original approval of BLA 125469 on 18 September 2014 for glycaemic control in adults with type 2 diabetes.
Why it matters. A once-weekly GLP-1 agonist without a weight-management indication; the workbook's 'FDA expiry 2024' refers to patent status, not to the approval, and is quarantined.
Event
Approval
Indication
Type 2 diabetes (glycaemic control) (Adjunct to diet and exercise)
Once-weekly GLP-1 receptor agonist for type 2 diabetes.
United Kingdom
No verified events recorded yet. Regulator: MHRA.
United States
· Approval Confirmed
FDA approves Trulicity (dulaglutide) for type 2 diabetes
Trulicity (once-weekly injection) · Type 2 diabetes (glycaemic control)
Original approval of BLA 125469 on 18 September 2014 for glycaemic control in adults with type 2 diabetes.
Why it matters: A once-weekly GLP-1 agonist without a weight-management indication; the workbook's 'FDA expiry 2024' refers to patent status, not to the approval, and is quarantined.
No verified events recorded yet. Regulator: EMA / European Commission.
This list is the complete, accessible view of the tracker; the board above draws from exactly the same records. Every entry is labelled Confirmed (official record), Company target (a dated sponsor statement), Regulator target (an official decision date, not a guarantee), GLPInfo estimate (an editorial range with assumptions) or Timing unknown. An approval is never inferred from a target date passing.